Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €170.19 EUR
Change Today +0.98 / 0.58%
Volume 179.0
ILU On Other Exchanges
As of 1:39 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILU) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/15 - €189.00
52 Week Low
04/15/14 - €92.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ILLUMINA INC (ILU)

illumina inc (ILU) Details

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms consist of HiScan and iScan systems, as well as NextSeq 550 system that are array scanners for DNA and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis. It also offers various library preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping, noninvasive prenatal test, and whole-genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has a collaboration agreement with Merck Serono to develop a sequencing-based oncology diagnostic. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,700 Employees
Last Reported Date: 02/18/15
Founded in 1998

illumina inc (ILU) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.1M
President and Director
Total Annual Compensation: $153.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $447.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $457.1K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $235.6K
Compensation as of Fiscal Year 2013.

illumina inc (ILU) Key Developments

Illumina, Inc. Selects Albiogen Ltd. as Distributor for Eastern European Market

Illumina Inc. has selected Albiogen Ltd. as its distributor for the Eastern European market. Albiogen will expand the reach of Illumina's array of next-generation sequencing platforms and solutions across the Russian Federation and Commonwealth of Independent States. Customers will have full access to Illumina's products and services, including the world's most comprehensive NGS systems, assays, and core consumables.

Illumina, Inc. Launches TruSight HLA

Illumina Inc. has launched TruSight HLA, a new research solution that provides accurate sequencing of Human Leukocyte Antigen, or HLA, region of the genome. Leveraging the MiSeq Sequencing System, the kit includes the TruSight HLA Sequencing Panel, a single assay for ultra-high resolution analysis of all the key genes within the major histocompatibility complex (MHC), reagents for preparing and sequencing DNA libraries, and optimized data analysis with software from Conexio Genomics. TruSight HLA uses a single assay and generates results based on 65,000 base pairs, a ten-fold increase in sequence coverage, which significantly streamlines the workflow while greatly expanding the capacity to discover novel alleles. TruSight HLA leverages Illumina sequencing by synthesis chemistry, the most trusted NGS technology. HLA typing researchers can use the solution to replace the multiple rounds of testing and the dozens of assays currently necessary to resolve ambiguous results. Through a streamlined workflow and multiplexed samples, this single assay and tightly integrated software enable labs to reduce hands-on time, decrease costs, improve productivity, and increase confidence in the results, while generating unambiguous, phase-resolved HLA typing results in less than four days.

Illumina, Inc. Announces Strategic Collaboration with Merck Serono to Expand Companion Diagnostics for Oncology

Illumina Inc. announced it has formed a collaboration with Merck Serono to develop a universal next-generation sequencing-based oncology diagnostic. In addition to separate collaborations with AstraZeneca, Janssen Biotech Inc., and Sanofi, Illumina and Merck Serono will work to create a universal test system for clinical trials of targeted cancer therapies, with the goal of a more comprehensive tool for precision medicine. Illumina is working with Merck Serono to develop assays that detect and measure multiple variants simultaneously to support clinical trials. The collaboration toward the universal cancer test will include test development, worldwide regulatory approvals, and global commercialization. In parallel, Illumina continues to collaborate with the key thought leaders of the Actionable Genome Consortium to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILU:GR €170.19 EUR +0.98

ILU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Avago Technologies Ltd $128.21 USD +3.50
Dr Reddy's Laboratories Ltd 3,415 INR 0.00
Hologic Inc $32.49 USD +0.55
Sigma-Aldrich Corp $138.21 USD -0.02
Waters Corp $124.11 USD +2.26
View Industry Companies

Industry Analysis


Industry Average

Valuation ILU Industry Range
Price/Earnings 78.9x
Price/Sales 14.3x
Price/Book 18.4x
Price/Cash Flow 68.5x
TEV/Sales 13.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at